102 related articles for article (PubMed ID: 15729694)
1. Pilot screening programme for small molecule activators of p53.
Berkson RG; Hollick JJ; Westwood NJ; Woods JA; Lane DP; Lain S
Int J Cancer; 2005 Jul; 115(5):701-10. PubMed ID: 15729694
[TBL] [Abstract][Full Text] [Related]
2. Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2'-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells.
Pulukuri SM; Rao JS
Int J Oncol; 2005 Apr; 26(4):863-71. PubMed ID: 15753979
[TBL] [Abstract][Full Text] [Related]
3. Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway.
Pamment J; Ramsay E; Kelleher M; Dornan D; Ball KL
Oncogene; 2002 Nov; 21(51):7776-85. PubMed ID: 12420214
[TBL] [Abstract][Full Text] [Related]
4. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage.
Price BD; Youmell MB
Cancer Res; 1996 Jan; 56(2):246-50. PubMed ID: 8542574
[TBL] [Abstract][Full Text] [Related]
5. RelB inhibits cell proliferation and tumor growth through p53 transcriptional activation.
Jacque E; Billot K; Authier H; Bordereaux D; Baud V
Oncogene; 2013 May; 32(21):2661-9. PubMed ID: 22777360
[TBL] [Abstract][Full Text] [Related]
6. A novel approach to cancer treatment using structural hybrids of the p53 gene family.
Sasaki Y; Oshima Y; Koyama R; Tamura M; Kashima L; Idogawa M; Yamashita T; Toyota M; Imai K; Shinomura Y; Tokino T
Cancer Gene Ther; 2012 Nov; 19(11):749-56. PubMed ID: 22956039
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents.
Peltonen K; Colis L; Liu H; Jäämaa S; Moore HM; Enbäck J; Laakkonen P; Vaahtokari A; Jones RJ; af Hällström TM; Laiho M
PLoS One; 2010 Sep; 5(9):e12996. PubMed ID: 20885994
[TBL] [Abstract][Full Text] [Related]
8. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.
Gagnebin J; Kovar H; Kajava AV; Estreicher A; Jug G; Monnier P; Iggo R
Oncogene; 1998 Feb; 16(5):685-90. PubMed ID: 9482117
[TBL] [Abstract][Full Text] [Related]
9. Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage.
Cox LS; Lane DP
Bioessays; 1995 Jun; 17(6):501-8. PubMed ID: 7575491
[TBL] [Abstract][Full Text] [Related]
10. p53-Dependent growth arrest and altered p53-immunoreactivity following metabolic labelling with 32P ortho-phosphate in human fibroblasts.
Bond JA; Webley K; Wyllie FS; Jones CJ; Craig A; Hupp T; Wynford-Thomas D
Oncogene; 1999 Jun; 18(25):3788-92. PubMed ID: 10391688
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1.
Huang SM; Schönthal AH; Stallcup MR
Oncogene; 2001 Apr; 20(17):2134-43. PubMed ID: 11360197
[TBL] [Abstract][Full Text] [Related]
12. Additive effect between NF-kappaB subunits and p53 protein for transcriptional activation of human p53 promoter.
Benoit V; Hellin AC; Huygen S; Gielen J; Bours V; Merville MP
Oncogene; 2000 Sep; 19(41):4787-94. PubMed ID: 11032029
[TBL] [Abstract][Full Text] [Related]
13. The p53 tumour suppressor gene.
Steele RJ; Thompson AM; Hall PA; Lane DP
Br J Surg; 1998 Nov; 85(11):1460-7. PubMed ID: 9823903
[TBL] [Abstract][Full Text] [Related]
14. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
[TBL] [Abstract][Full Text] [Related]
15. p53 translational control: a new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics.
Halaby MJ; Yang DQ
Gene; 2007 Jun; 395(1-2):1-7. PubMed ID: 17395405
[TBL] [Abstract][Full Text] [Related]
16. The apoptotic and transcriptional transactivation activities of p53 can be dissociated.
Bissonnette N; Wasylyk B; Hunting DJ
Biochem Cell Biol; 1997; 75(4):351-8. PubMed ID: 9493957
[TBL] [Abstract][Full Text] [Related]
17. Induction of genetic instability by gain-of-function p53 cancer mutants.
Xu Y
Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
[TBL] [Abstract][Full Text] [Related]
18. Improving cancer therapy by non-genotoxic activation of p53.
Lain S; Lane D
Eur J Cancer; 2003 May; 39(8):1053-60. PubMed ID: 12736103
[TBL] [Abstract][Full Text] [Related]
19. The role of DNA damage responses in p53 biology.
Speidel D
Arch Toxicol; 2015 Apr; 89(4):501-17. PubMed ID: 25618545
[TBL] [Abstract][Full Text] [Related]
20. p51A (TAp63gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation.
Katoh I; Aisaki KI; Kurata SI; Ikawa S; Ikawa Y
Oncogene; 2000 Jun; 19(27):3126-30. PubMed ID: 10871867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
